The 21st Century Cures Act was signed into law on December 13, 2016. The Act addresses acceleration of medical product discovery, development, and delivery. During this webinar we will examine the affect the 21st Century Cures Act has, and will continue to have, on the U.S. Food & Drug Administration (FDA) as well as the impact on FDA-regulated industries.

In addition, we will also discuss:

  • How the 21st Century Cures Act incorporates measures and funding intended to help Americans with mental illness get the care they need. We will examine the ways in which the Act elevated behavioral health in the context of overall health policy and discuss the manner in which key stakeholders can access and take advantage of the landmark mental health provisions in the Act.
  • How to take advantage of the billion-dollar infusion to the NIH and the potential implications the infusion may have on researchers and companies. We will also discuss the "Patents 4 Patients" program which is intended to provide significant benefits to entities seeking patent protection for cancer therapies.

This webinar is part of our Hot Topics in Health Care Webinar/Seminar Series highlighting important health care topics throughout the year. The next webinar in this series, scheduled for March 29, 2017, will focus on the transition from the Affordable Care Act.

Date & Time

Thursday, March 23, 2017
12:00 PM - 1:00 PM ET


Neil P. DiSpirito
Life Sciences and Technology


Scott D. Marty, PhD
Intellectual Property

John Devine
Health Care

This program is open to Ballard Spahr clients and prospective clients and those interested in developments in the health care industry. There is no cost to attend. This program is not eligible for CLE credits.

Please register at least two days before the webinar. Login details will be sent to all approved registrants. For more information, contact Daniel Martin at